BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 26260109)

  • 21. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
    J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.
    Qian MY; Yuwei J R; Angus P; Schelleman T; Johnson L; Gow P
    J Gastroenterol Hepatol; 2010 May; 25(5):951-6. PubMed ID: 20546449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
    Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
    J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
    Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating patients with cirrhosis for hepatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein.
    Paul SB; Gulati MS; Sreenivas V; Madan K; Gupta AK; Mukhopadhyay S; Acharya SK
    Oncology; 2007; 72 Suppl 1():117-23. PubMed ID: 18087192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C.
    Bayati N; Silverman AL; Gordon SC
    Am J Gastroenterol; 1998 Dec; 93(12):2452-6. PubMed ID: 9860408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.
    El-Serag HB; Kramer JR; Chen GJ; Duan Z; Richardson PA; Davila JA
    Gut; 2011 Jul; 60(7):992-7. PubMed ID: 21257990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
    Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
    J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis.
    Singal AG; Tayob N; Mehta A; Marrero JA; El-Serag H; Jin Q; Saenz de Viteri C; Fobar A; Parikh ND
    Hepatology; 2022 Mar; 75(3):541-549. PubMed ID: 34618932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis.
    Snowberger N; Chinnakotla S; Lepe RM; Peattie J; Goldstein R; Klintmalm GB; Davis GL
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1187-94. PubMed ID: 17944733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C.
    Bruce MG; Bruden D; McMahon BJ; Christensen C; Homan C; Sullivan D; Deubner H; Williams J; Livingston SE; Gretch D
    J Viral Hepat; 2008 Mar; 15(3):179-87. PubMed ID: 18233991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.
    Wang M; Devarajan K; Singal AG; Marrero JA; Dai J; Feng Z; Rinaudo JA; Srivastava S; Evans A; Hann HW; Lai Y; Yang H; Block TM; Mehta A
    Cancer Prev Res (Phila); 2016 Feb; 9(2):172-9. PubMed ID: 26712941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B.
    Wun YT; Dickinson JA
    Cochrane Database Syst Rev; 2003; (2):CD002799. PubMed ID: 12804438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir.
    Wong GL; Chan HL; Tse YK; Chan HY; Tse CH; Lo AO; Wong VW
    Hepatology; 2014 Mar; 59(3):986-95. PubMed ID: 24123097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis.
    Sarwar S; Khan AA; Tarique S
    J Coll Physicians Surg Pak; 2014 Jan; 24(1):18-22. PubMed ID: 24411536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?
    Singal AG; Nehra M; Adams-Huet B; Yopp AC; Tiro JA; Marrero JA; Lok AS; Lee WM
    Am J Gastroenterol; 2013 Mar; 108(3):425-32. PubMed ID: 23337478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
    Moon AM; Weiss NS; Beste LA; Su F; Ho SB; Jin GY; Lowy E; Berry K; Ioannou GN
    Gastroenterology; 2018 Oct; 155(4):1128-1139.e6. PubMed ID: 29981779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.